Finance Watch: Arbor, Acrivon, Bit.Bio Close VC Mega-Rounds
Mission BioCapital Raises $275m For Fund V
Executive Summary
Private Company Edition: Arbor is developing drugs based on proprietary gene editors, Acrivon is applying proteomics to precision cancer therapies, and bit.bio is producing differentiated cell products. Also, Marengo launches with $80m, Sanofi invests up to $60m in Gyroscope and Shasqi raises $50m.
You may also be interested in...
Finance Watch: 2021 Biopharma VC Funding Tops Full-Year 2020 Total
Private Company Edition: The industry raised $28bn in venture capital through the third quarter, breaking the record $27.4bn raised last year. Also, big pharmas backed a start-up lab in Israel, plus mega-rounds for CinCor Pharma ($143m) and Rectify Pharmaceuticals ($100m), while Cerecin raises $40m.
Deal Watch: Lilly Teams Up With Lycia In Protein Degradation
Lilly hopes to address immunology and pain indications with biotech’s LYTAC technology. Sunovion licenses European rights to Parkinson’s therapy Kynmobi to Bial.
Laronde Aims To Advance Its eRNA Therapies In Eight Weeks, And Has $440m To Help
The Flagship Pioneering-founded start-up will build a “Gigabase Factory” to go from idea to in vivo proof of concept within eight weeks by rapidly manufacturing and running preclinical tests for multiple constructs at once.